No biotech investor likes when a large percentage of patients walk away from an important clinical trial. After Annexon (NASDAQ: ANNX) revealed that this occurred in an otherwise encouraging study of its ANX005, a pipeline drug aimed at treating Huntington's disease, the company's shares tumbled by over 34% on the day.
After market hours on Tuesday, Annexon reported interim results from an ongoing, open-label Phase 2 clinical trial of ANX005. The data concerned patients who completed the full 24-week course of treatment and revealed that the drug demonstrated "full target engagement of C1q in both serum and cerebrospinal fluid observed in evaluable patients through the dosing period."
Image source: Getty Images.
For further details see:
Why Annexon Biosciences Stock Plummeted 34% Today